Literature DB >> 33439936

Down-regulation of HCP5 inhibits cell proliferation, migration, and invasion through regulating EPHA7 by competitively binding miR-101 in osteosarcoma.

Yangmao Tu1, Qing Cai1, Xuemei Zhu2, Min Xu3.   

Abstract

Patients with osteosarcoma (OS) usually have poor overall survival because of frequent metastasis. Long non-coding RNAs (lncRNAs) have been reported to be associated with tumorigenesis and metastasis. In this study, we investigated the expression and roles of lncRNA human histocompatibility leukocyte antigen (HLA) complex P5 (HCP5) in OS, aiming to provide a novel molecular mechanism for OS. HCP5 was up-regulated both in OS tissues and cell lines and high expression of HCP5 was associated to low survival in OS patients. Down-regulation of HCP5 inhibited cell proliferation, migration, and invasion, suggesting its carcinogenic role in OS. miR-101 was targeted by HCP5 and its expression was decreased in OS. The inhibitor of miR-101 reversed the impact of HCP5 down-regulation on cell proliferation, apoptosis, and metastasis in OS. Ephrin receptor 7 (EPHA7) was proved to be a target of miR-101 and had ability to recover the effects of miR-101 inhibitor in OS. In conclusion, lncRNA HCP5 knockdown suppressed cell proliferation, migration, and invasion, and induced apoptosis through depleting the expression of EPHA7 by binding to miR-101, providing a potential therapeutic strategy of HCP5 in OS.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33439936      PMCID: PMC7798137          DOI: 10.1590/1414-431X20209161

Source DB:  PubMed          Journal:  Braz J Med Biol Res        ISSN: 0100-879X            Impact factor:   2.590


  33 in total

1.  Knockdown of HCP5 exerts tumor-suppressive functions by up-regulating tumor suppressor miR-128-3p in anaplastic thyroid cancer.

Authors:  Jing Chen; Dongjing Zhao; Qiang Meng
Journal:  Biomed Pharmacother       Date:  2019-05-16       Impact factor: 6.529

Review 2.  Recent advances in osteosarcoma.

Authors:  Sander M Botter; Dario Neri; Bruno Fuchs
Journal:  Curr Opin Pharmacol       Date:  2014-03-13       Impact factor: 5.547

3.  Long noncoding RNA HCP5 contributes to epithelial-mesenchymal transition in colorectal cancer through ZEB1 activation and interacting with miR-139-5p.

Authors:  Cheng Yang; Junjun Sun; Weifeng Liu; Yanhui Yang; Zhijie Chu; Tianbao Yang; Yang Gui; Du Wang
Journal:  Am J Transl Res       Date:  2019-02-15       Impact factor: 4.060

Review 4.  miRNA Deregulation in Cancer Cells and the Tumor Microenvironment.

Authors:  Rajesha Rupaimoole; George A Calin; Gabriel Lopez-Berestein; Anil K Sood
Journal:  Cancer Discov       Date:  2016-02-10       Impact factor: 39.397

5.  Comparative genetic analyses point to HCP5 as susceptibility locus for HCV-associated hepatocellular carcinoma.

Authors:  Christian M Lange; Stéphanie Bibert; Jean-François Dufour; Cristina Cellerai; Andreas Cerny; Markus H Heim; Laurent Kaiser; Raffaele Malinverni; Beat Müllhaupt; Francesco Negro; David Semela; Darius Moradpour; Zoltán Kutalik; Pierre-Yves Bochud
Journal:  J Hepatol       Date:  2013-05-09       Impact factor: 25.083

6.  MicroRNA-101 inhibits the metastasis of osteosarcoma cells by downregulation of EZH2 expression.

Authors:  Kailiang Zhang; Yinglong Zhang; Kun Ren; Guangyi Zhao; Kang Yan; Baoan Ma
Journal:  Oncol Rep       Date:  2014-09-02       Impact factor: 3.906

7.  Eph receptor function is modulated by heterooligomerization of A and B type Eph receptors.

Authors:  Peter W Janes; Bettina Griesshaber; Lakmali Atapattu; Eva Nievergall; Linda L Hii; Anneloes Mensinga; Chanly Chheang; Bryan W Day; Andrew W Boyd; Philippe I Bastiaens; Claus Jørgensen; Tony Pawson; Martin Lackmann
Journal:  J Cell Biol       Date:  2011-12-05       Impact factor: 10.539

Review 8.  Noncoding RNA in oncogenesis: a new era of identifying key players.

Authors:  Guorui Deng; Guangchao Sui
Journal:  Int J Mol Sci       Date:  2013-09-05       Impact factor: 5.923

Review 9.  Osteosarcoma Overview.

Authors:  Brock A Lindsey; Justin E Markel; Eugenie S Kleinerman
Journal:  Rheumatol Ther       Date:  2016-12-08

10.  HCP5 is a SMAD3-responsive long non-coding RNA that promotes lung adenocarcinoma metastasis via miR-203/SNAI axis.

Authors:  Lin Jiang; Ranran Wang; Li Fang; Xiaolu Ge; Lingna Chen; Ming Zhou; Yanhong Zhou; Wei Xiong; Yerong Hu; Xianming Tang; Guiyuan Li; Zheng Li
Journal:  Theranostics       Date:  2019-04-13       Impact factor: 11.556

View more
  4 in total

Review 1.  The EPH/Ephrin System in Bone and Soft Tissue Sarcomas' Pathogenesis and Therapy: New Advancements and a Literature Review.

Authors:  Argyris C Hadjimichael; Alexandros Pergaris; Angelos Kaspiris; Athanasios F Foukas; Stefania Kokkali; Gerasimos Tsourouflis; Stamatios Theocharis
Journal:  Int J Mol Sci       Date:  2022-05-05       Impact factor: 6.208

2.  Long Noncoding RNA HCP5 Contributes to Nasopharyngeal Carcinoma Progression by Targeting MicroRNA-128-3p.

Authors:  Gangyong Miao; Bin Liu; Keji Ling; Tao Peng; En Zhou; Sijun Xie; Zhiqiang Tan
Journal:  J Oncol       Date:  2022-05-12       Impact factor: 4.501

Review 3.  The role of EphA7 in different tumors.

Authors:  Xiangyi Chen; Dechen Yu; Haiyu Zhou; Xiaobo Zhang; Yicun Hu; Ruihao Zhang; Xidan Gao; Maoqiang Lin; Taowen Guo; Kun Zhang
Journal:  Clin Transl Oncol       Date:  2022-02-02       Impact factor: 3.405

Review 4.  LncRNA HCP5 as a potential therapeutic target and prognostic biomarker for various cancers: a meta‑analysis and bioinformatics analysis.

Authors:  Shao-Pu Hu; Meng-Xue Ge; Lei Gao; Min Jiang; Kai-Wen Hu
Journal:  Cancer Cell Int       Date:  2021-12-19       Impact factor: 5.722

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.